Several of these clinical studies are evaluating the benefit of PI3K/AKT/mTOR inhibition in association with immune checkpoint inhibitors in patients with colorectal, lung, leukemia, or other solid tumors (Table 2). This evidence concerns the gene PIK3CA and leukemia.